
DBVT Stock Forecast & Price Target
DBVT Analyst Ratings
Bulls say
DBV Technologies is a clinical-stage specialty biopharmaceutical company with a strong pipeline and innovative technology platform focused on developing treatments for food allergies, including the potentially game-changing Viaskin Peanut patch. The company has a robust financial position with a cash runway into 2027, providing stability for future growth. While there are clinical, regulatory, and commercial risks involved, DBV has a strong chance of revolutionizing the field of immunotherapy and has potential for significant long-term success, making it a positive investment opportunity.
Bears say
DBV Technologies is facing potential setbacks and delays in their development of Viaskin Peanut, their lead candidate for peanut-allergic patients. These delays include new adverse findings in their ongoing safety study for toddlers and potential competition emerging in the immunotherapy space. Additionally, the company's Viaskin platform has already faced regulatory hurdles, with the FDA requesting additional safety studies. These challenges, combined with the potential for competing treatments, could hinder DBV Technologies' growth potential and stock performance in the long term.
This aggregate rating is based on analysts' research of DBV Technologies SA Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.
DBVT Analyst Forecast & Price Prediction
Start investing in DBVT
Order type
Buy in
Order amount
Est. shares
0 shares